Brian Diffey 2006 Phys. Med. Biol. 51 R229 doi:10.1088/0031-9155/51/13/R14
Brian Diffey
Show affiliationsPsoralen photochemotherapy (PUVA) is the combined treatment of skin disorders with a photosensitizing drug (Psoralen) and UltraViolet A radiation. The introduction of PUVA therapy has arguably been the most important development in dermatology over the past 30 years and from the first days of the treatment being introduced in the UK, British medical physicists were an integral part of the effort to establish it. Medical physicists have contributed to this development in a number of ways, from designing irradiation units in the early days of the technique, through to collaborating with dermatologists in prosecuting clinical and experimental studies aimed at improving patient outcomes. That the dose of UVA radiation is administered quantitatively, and not qualitatively, has probably been the single most important contribution made by several medical physicists over this period. However, despite concerns that were expressed almost 30 years ago about the accuracy with which UVA doses are administered to patients, the medical physics community still has some way to go before we can be satisfied that statements about UVA irradiance and dose can be made with confidence.
87.50.wp Therapeutic applications
87.56.-v Radiation therapy equipment
Issue 13 (7 July 2006)
Received 20 December 2005, in final form 21 February 2006
Published 20 June 2006
Brian Diffey 2006 Phys. Med. Biol. 51 R229
D. C. B. Whittet et al. 2004 ApJ 602 291
Saeyoung Shin et al. 2005 ApJ 619 407
F Liu and Y Lu 2007 J. Phys. G: Nucl. Part. Phys. 34 S1073
Hélène M. L. G. Flohic et al. 2006 ApJ 647 140
C Z Bi et al 2005 J. Phys.: Condens. Matter 17 5225
P Dita 2004 J. Phys. A: Math. Gen. 37 5355
A. Borio di Tigliole et al 2004 Europhys. Lett. 67 1045
Dževad Belkić 2006 Phys. Med. Biol. 51 6483
Kazuki Yabushita et al 2007 J. Phys. A: Math. Theor. 40 8403